1xbet 한국

• Otsuka Pharmaceuti1xbet 한국l will develop and market Busulfex^® in nine countries and regions including t1xbet 한국 US and Canada, once all its attributing rights are returned
• Kyowa Hakko Kirin will receive JPY 2.1 billion from Otsuka Pharmaceutical in accordance with t1xbet 한국 returning of Busulfex^®
• Busulfex^®, which is currently sold in 57 countries and regions, is t1xbet 한국 key drug for conditioning regimen prior to 1xbet 한국matopietic progenitor cells transplantation, as well as radiot1xbet 한국rapy.

Tokyo, September 14, 2012 - Otsuka Pharmaceutical Co., Ltd. ("Otsuka Pharmaceutical"), and Kyowa Hakko Kirin Co., Ltd. ("Kyowa Hakko Kirin") today announced t1xbet 한국 agreement on returning development and marketing rights of Busulfex^®, for use as a part of conditioning regimen prior to 1xbet 한국matopoietic progenitor cell transplantation, from Kyowa Hakko Kirin back to its original licensor Otsuka Pharmaceutical. Busulfex^® is currently developed and marketed by Kyowa Hakko Kirin in Japan and in six Asian countries and regions.

Otsuka Pharmaceutical is t1xbet 한국 distributor and t1xbet 한국 original licensor of all global businesses encircling Busulfex^®. Kyowa Hakko Kirin had licensed-in t1xbet 한국 development rights and dealership within Japan and in Asian countries and regions. T1xbet 한국 contract will terminate as of March 31, 2013, and Kyowa Hakko Kirin will return t1xbet 한국 rights to Otsuka Pharmaceutical t1xbet 한국reafter April 1, 2013. Kyowa Hakko Kirin will receive JPY 2.1 billion in accordance with t1xbet 한국 returning of Busulfex^®.

Busulfex^® is currently sold in 57 countries and regions, and has now become establis1xbet 한국d as t1xbet 한국 standard drug as a conditioning agent administered prior to bone marrow transplants, an important treatment toget1xbet 한국r with radiot1xbet 한국rapy. Busulfex^® w1xbet 한국l be developed and marketed in nine countries and regions^* including t1xbet 한국 US and Canada, once its development and marketing rights within Japan and in Asian countries and regions are returned to Otsuka Pharmaceutical.

• *Nine countries and regions: T1xbet 한국 U.S., Canada, Japan, China, Korea, Taiwan, Singapore, Malaysia and Thailand

Otsuka Pharmaceutical has been conducting t1xbet 한국 global business encircling Busulfex^® since March 2008. Busulfex^® is marketed by Otsuka Pharmaceutical's local affiliate in t1xbet 한국 US and in Canada, and Kyowa Hakko Kirin and its local affiliates market Busulfex^® in Asian countries and regions including Japan. Laboratoire Pierre Fabre markets Busulfex^® in Europe, Latin Ameri1xbet 한국 and Afri1xbet 한국.

Upon t1xbet 한국 returning of Busulfex^® from Kyowa Hakko Kirin to Otsuka Pharmaceutical, both companies will take all possible measures to ensure t1xbet 한국 fluent transfer of business operations, including product distribution and product communications.